MOVERS: DSTM SUNW GNSM IOM... Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MOVERS: DSTM SUNW GNSM IOM...

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: hoyasaxa who wrote ()	10/25/1996 10:14:00 AM
From: hoyasaxa	of 22

09:25 ET ****** __GILEAD SCIENCES (GILD) 25 CLOSED. Company reported extremely strong 3rd qtr financial results. First, company blew-out earnings estimates that called for a loss of $0.26 a share by reporting net income of $0.30 a share. Figure was also well ahead of year-ago's $0.40 a share net loss. Fact that consensus estimate consisted of only two analysts' surveyed, one with loss estimate of $0.07 the other -$0.45, detracts from strong earnings number to some degree. One cannot, however, overlook the strength of the numbers that company reported. For the period, total revenue increased to $26.7 million from $1.1 million. In latest qtr company benefitted from strong sales of Vistide, a treatment for cytomegalovirus retinitis in patients with AIDS that was approved by the FDA in late June. Expect company to benefit in future qtrs from major partnership pacts inked during the latest qtr. One of the deals was with Pharmacia & Upjohn, estimated to be worth $60 million, to market Vistide outside of the US. Major long-term worry is further concern over Vistide causing kidney toxicity. Otherwise, stock should be a strong intermediate and long-term performer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next